# A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

> **NCT05877547** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 381 (actual)

## Conditions studied

- Non-alcoholic Fatty Liver Disease
- Fatty Liver, Nonalcoholic
- NAFLD
- Nonalcoholic Fatty Liver Disease
- Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** Efinopegdutide
- **DRUG:** Semaglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05877547
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-23
- **Primary completion:** 2025-12-29
- **Final completion:** 2025-12-29
- **Target enrollment:** 381 (ACTUAL)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05877547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05877547, "A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05877547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*